Francis J. Martin, PhD | Authors

Future Prospects for Stealth Liposomes in Cancer Therapy

October 01, 1997

While doxorubicin (Adriamycin) is among the most active single agents in the treatment of breast cancer and other solid tumors, its concomitant toxicity limits its use. Quality-of-life issues have driven the search for gentler,

Pegylated Liposomal Doxorubicin: Scientific Rationale and Preclinical Pharmacology

October 01, 1997

Liposome-encapsulated drug delivery is a methodology that has been evolving over the past 30 years. A number of liposome-encapsulated anthracycline products are in development and two, pegylated liposomal doxorubicin